Skye Bioscience, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Significant Contracts (Detail Textuals)

Significant Contracts (Detail Textuals)			1 Months Ended
Significant Contracts (Detail Textuals)	Jan. 10, 2017 USD ($)	Dec. 14, 2015 USD ($) License_agreement	Dec. 31, 2018 USD ($)	Jul. 31, 2018 USD ($)	Sep. 29, 2014 USD ($) License_agreement	Nov. 30, 2018 USD ($)	Aug. 31, 2018 USD ($)
UM 5050 pro-drug agreements \| University of Mississippi \| Intellectual Property
Significant Contracts [Line Items]
Number of license agreements \| License_agreement					3
Notice period for termination					60 days
Annual fees for license agreement					$ 25,000
Aggregate milestone payments if milestones achieved					$ 700,000
UM 8930 analogue agreements \| University of Mississippi \| Intellectual Property
Significant Contracts [Line Items]
Number of license agreements \| License_agreement		2
Notice period for termination		60 days
Annual fees for license agreement		$ 25,000
Aggregate milestone payments if milestones achieved		$ 700,000
UM 5070 license agreement \| University of Mississippi \| Intellectual Property
Significant Contracts [Line Items]
Term of agreement	1 year
Notice period for termination	60 days
Annual fees for license agreement	$ 25,000
Aggregate milestone payments if milestones achieved	$ 700,000
Research Agreement \| University of Mississippi
Significant Contracts [Line Items]
Payments due for aggregate amount							$ 155,156
Master service agreement \| Glauconix Biosciences, Inc
Significant Contracts [Line Items]
Payments due for aggregate amount						$ 180,424
Letter agreement ("Agreement") \| AMRI
Significant Contracts [Line Items]
Estimated agreement fees and expenses				$ 64,200
Incremental agreement fees and expenses			$ 71,800